MCM
NKTR icon

M28 Capital Management’s Nektar Therapeutics NKTR Stock Holding History

M28 Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-37,373
Closed -$7.57M – 14
2021
Q4 		$7.57M Buy
+37,373
New +$8.11M 5.91% 8

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

M28 Capital Management's NKTR Position: Q1 2022 in Review

M28 Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 37,373 shares — an estimated $7.57M sold.

M28 Capital Management first reported a position in NKTR in Q4 2021 and held it in 1 quarter. The position peaked at $7.57M in Q4 2021. 240 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

  • M28 Capital Management reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • M28 Capital Management sold 37,373 Nektar Therapeutics shares in Q1 2022, an estimated $7.57M.
  • M28 Capital Management first reported a position in Nektar Therapeutics in Q4 2021 and held it in 1 quarter.
  • M28 Capital Management's Nektar Therapeutics position peaked at $7.57M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on M28 Capital Management's 13F filing for Q1 2022, filed 13 May 2022.